A systematic UHPLC-Q-TOF-MS/MS-based strategy for analysis of chemical constituents and related in vivo metabolites of Buyang Huanwu decoction.

Autor: Xiong Q; MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an 223003, Jiangsu, China; National Postdoctoral Rresearch Workstation, Anhui China Resources Jinchan Pharmaceutical Co., LTD, Huaibei, 235000, Anhui, China., Li H; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an 223003, Jiangsu, China., Yan Y; Clinical Pharmacy Center, The First Affiliated Hospital of Kunming Medical University, Kunming, 650000, Yunnan, China., Yan Z; Department of Pharmacy, Huai 'an Hospital of Traditional Chinese Medicine (Affiliated Hospital of Nanjing University of Traditional Chinese Medicine), Huai'an 223002, Jiangsu, China., Shi Y; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an 223003, Jiangsu, China., Wang R; National Postdoctoral Rresearch Workstation, Anhui China Resources Jinchan Pharmaceutical Co., LTD, Huaibei, 235000, Anhui, China., Cheng S; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an 223003, Jiangsu, China., Deng Z; College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, China., Zheng G; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an 223003, Jiangsu, China., Tao M; Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an 223003, Jiangsu, China., Cao X; Department of Neurology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an 223001, Jiangsu, China. Electronic address: cxy0707@126.com., Yu Y; Department of Neurology, Lianshui County People's Hospital, Huai'an 223400, Jiangsu, China. Electronic address: Ls_yyd@163.com., He D; National Postdoctoral Rresearch Workstation, Anhui China Resources Jinchan Pharmaceutical Co., LTD, Huaibei, 235000, Anhui, China. Electronic address: jswangr@999.com.cn., Peng D; MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China. Electronic address: pengdaiyin@163.com.
Jazyk: angličtina
Zdroj: Journal of ethnopharmacology [J Ethnopharmacol] 2025 Jan 30; Vol. 337 (Pt 3), pp. 118987. Date of Electronic Publication: 2024 Oct 22.
DOI: 10.1016/j.jep.2024.118987
Abstrakt: Ethnopharmacological Relevance: Buyang Huanwu Decoction (BYHWD), a traditional Chinese medicine, is one of the classic prescriptions for the treatment of ischemic stroke in clinical practice. It has the effects of tonifying qi, activating blood circulation, and promoting meridian circulation. However, its chemical analysis has not been clarified, which greatly hinders its further clinical application. Therefore, it is necessary to clarify the chemical constituents and metabolites profile of BYHWD in vivo.
Aim of the Study: Characterizing the chemical basis of BYHWD in vitro, and combing studies of related metabolism in vivo to screen out the potential active components of BYHWD with pharmacological effects in vivo.
Materials and Methods: Twelve male rats weighed 200 ± 20 each were selected for the experiments. According to the fragmentation of different structural types of components and diagnostic ions, UHPLC-Q-TOF-MS/MS was used to classify and clarify the unknown components of BYHWD and identify the material basis of BYHWD in vitro. Then, rat plasma, tissues, feces, and urine were collected for analysis. Based on the similarity of MS responses (accurate molecular weight and secondary fragmentation) and chromatographic behavior (retention time), the in vivo prototype and metabolites were analyzed. Through the phase I and phase II metabolism law, a metabolite library was established to analyze the prototype-matched metabolites.
Results: A total of 121 in vitro compounds and 55 in vivo prototypes of BYHWD were identified, corresponding to 123 matched prototypes. It was mainly composed of flavonoids, triterpene saponins, nucleosides and lactones both in vitro and in vivo. Quercetin, ligustilide, astragaloside IV, calycosin, paeoniflorin and ferulic acid were the main prototypes and metabolites in plasma and urine.
Conclusion: Quercetin, ligustilide, astragaloside IV, calycosin, paeoniflorin and ferulic acid were the main active ingredients of BYHWD.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: